Telo Therapeutics, Inc. — Form D/A
Telo Therapeutics, Inc. of SAN FRANCISCO, CA, a company, filed a Form D amendment with the SEC on 2022-06-21. The offering totals $10.2M, of which $4.7M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-06-21
- Form: D/A
- Accession: 0001868220-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.2M
- Amount sold: $4.7M
- Remaining: $5.4M
- Investors: 12
- Date of first sale: 2021-06-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-403696
Issuer
- Name: Telo Therapeutics, Inc.
- CIK: 0001868220
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 953 INDIANA STREET, SAN FRANCISCO, CA, 94107
- Phone: 831-234-8510
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Robert Bell | Director | San Francisco, CA |
| Robert G Blazej | Director | San Francisco, CA |
| Joseph Costello | Director | San Francisco, CA |
| Michael D Taylor | Director | San Francisco, CA |
| Robert Bell | Executive Officer | San Francisco, CA |
Other filings by this issuer (1)
More